Anuh Pharma Adjusts Evaluation Score Amidst Mixed Financial Performance and Market Sentiment

Anuh Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a sideways position to a mildly bullish outlook.
Key financial metrics indicate that Anuh Pharma's current price stands at 208.05, with a previous close of 209.00. The stock has experienced a 52-week high of 249.95 and a low of 148.05, showcasing a range of volatility. In terms of returns, the stock has generated a -8.95% return over the past year, contrasting with a 6.46% return from the broader market.

Despite a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 3.4, the company has faced challenges, including a significant profit decline of -21.2% over the past year. Additionally, domestic mutual funds hold no stake in Anuh Pharma, which may suggest a cautious stance regarding its current valuation or business outlook.

For further insights into Anuh Pharma's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.